Dose-response and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial

Background: Most dialysis patients require phosphate binders to control hyperphosphatemia. Ferric citrate has been tested in phase 2 trials as a phosphate binder. This trial was designed as a dose-response and efficacy trial. Study design: Prospective, phase 3, multicenter, open-label, randomized clinical trial. Setting & participants: 151 participants with hyperphosphatemia on maintenance hemodialysis therapy. Intervention: […]